An update on current pharmacotherapy options for dyspepsia

Bibliography

• Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-87. e1-3
   PubMed Web of Science ®Google Scholar
• Aro P, Talley NJ, Agreus L, et al. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther 2011;33:1215-24
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-79
   PubMed Web of Science ®Google Scholar
• Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-37
   PubMed Web of Science ®Google Scholar
• Lacy BE, Talley NJ, Locke GR, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012;36:3-15
   PubMed Web of Science ®Google Scholar
• Fischler B, Tack J, De Gucht V, et al. Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 2003;124:903-10
   Google Scholar
• Sha W, Pasricha PJ, Chen JD. Correlations among electrogastrogram, gastric dysmotility, and duodenal dysmotility in patients with functional dyspepsia. J Clin Gastroenterol 2009;43:716-22
   Google Scholar
• Kusano M, Zai H, Shimoyama Y, et al. Rapid gastric emptying, rather than delayed gastric emptying, might provoke functional dyspepsia. J Gastroenterol Hepatol 2011;26(Suppl 3):75-8
   Google Scholar
• Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-81
   PubMed Web of Science ®Google Scholar
• McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74
   PubMed Web of Science ®Google Scholar
• Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000;14:317-24
   PubMed Web of Science ®Google Scholar
• Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011;171:1929-36
   PubMedGoogle Scholar
• Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81
   PubMed Web of Science ®Google Scholar
• Geeraerts B, Van Oudenhove L, Fischler B, et al. Influence of abuse history on gastric sensorimotor function in functional dyspepsia. Neurogastroenterol Motil 2009;21:33-41
   Google Scholar
• Clauwaert N, Jones MP, Holvoet L, et al. Associations between gastric sensorimotor function, depression, somatization, and symptom-based subgroups in functional gastroduodenal disorders: are all symptoms equal? Neurogastroenterol Motil 2012;24:1088-e565
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Aziz Q. Recent insights on central processing and psychological processes in functional gastrointestinal disorders. Dig Liver Dis 2009;41:781-7
   Google Scholar
• Talley NJ, Silverstein MD, Agreus L, et al. A technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998;114:582-95
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H(2)(15)O-PET study. Am J Gastroenterol 2010;105:913-24
   Google Scholar
• Holtmann G, Siffert W, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004;126:971-9
   PubMed Web of Science ®Google Scholar
• Zill P, Baghai TC, Zwanzger P, et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000;11:1893-7
   PubMed Web of Science ®Google Scholar
• Lindemann M, Virchow S, Ramann F, et al. The G protein beta3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Lett 2001;495:82-6
   PubMed Web of Science ®Google Scholar
• Baumgart D, Naber C, Haude M, et al. G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation. Circ Res 1999;85:965-9
   PubMedGoogle Scholar
• Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002;122:1738-47
   PubMed Web of Science ®Google Scholar
• Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129:98-104
   PubMed Web of Science ®Google Scholar
• Kindt S, Tertychnyy A, de Hertogh G, et al. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil 2009;21:832-e56
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011;106:1089-98
   PubMed Web of Science ®Google Scholar
• Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia. Aliment Pharmacol Ther 2010;31:1229-36
   PubMed Web of Science ®Google Scholar
• Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994;343:258-60
   PubMed Web of Science ®Google Scholar
• Ford AC, Ching E, Moayyedi P. Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. Aliment Pharmacol Ther 2009;30:28-36
   PubMed Web of Science ®Google Scholar
• Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1175-83
   PubMed Web of Science ®Google Scholar
• Miwa H, Ghoshal UC, Gonlachanvit S, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil 2012;18(2):150-68
   PubMed Web of Science ®Google Scholar
• Ang D. Measurement of gastric accommodation: a reappraisal of conventional and emerging modalities. Neurogastroenterol Motil 2011;23:287-91
   PubMed Web of Science ®Google Scholar
• Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006;23:923-36
   PubMed Web of Science ®Google Scholar
• Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002;50(Suppl 4):iv36-41
   PubMedGoogle Scholar
• Talley NJ. Review article: functional dyspepsia–should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995;9:107-15
   PubMedGoogle Scholar
• Witzel L, Gutz H, Huttemann W, et al. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995;9:19-24
   PubMed Web of Science ®Google Scholar
• Bratten J, Jones MP. Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system. J Clin Gastroenterol 2009;43:527-33
   Google Scholar
• George AA, Tsuchiyose M, Dooley CP. Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulcer dyspepsia. Gastroenterology 1991;101:3-6
   PubMed Web of Science ®Google Scholar
• Kato M, Watanabe M, Konishi S, et al. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther 2005;21(Suppl 2):27-31
   Google Scholar
• Saunders JH, Oliver RJ, Higson DL. Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J (Clinical research ed) 1986;292:665-8
   PubMed Web of Science ®Google Scholar
• Talley NJ, McNeil D, Hayden A, et al. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986;91:149-56
   PubMed Web of Science ®Google Scholar
• Nyren O, Adami HO, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986;314:339-43
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Shelly S, Deeks JJ, et al. WITHDRAWN: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev (Online) 2011;CD001960
   Google Scholar
• Peura DA, Kovacs TO, Metz DC, et al. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004;116:740-8
   PubMed Web of Science ®Google Scholar
• van Zanten SV, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol 2006;101:2096-106
   PubMed Web of Science ®Google Scholar
• Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65
   PubMed Web of Science ®Google Scholar
• Bolling-Sternevald E, Lauritsen K, Talley NJ, et al. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 2003;18:117-24
   Google Scholar
• Meineche-Schmidt V, Christensen E, Bytzer P. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study. Aliment Pharmacol Ther 2011;33:41-9
   Google Scholar
• van Marrewijk CJ, Mujakovic S, Fransen GA, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Lancet 2009;373:215-25
   Google Scholar
• Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, et al. Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start' and ‘H2-RA-start' management strategies in primary care–the CADET-HR Study. Aliment Pharmacol Ther 2005;21:1189-202
   PubMed Web of Science ®Google Scholar
• Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci 2010;55:2431-40
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Follow-Up to the January 26, 2009, Early Communication about an Ongoing Safety Review of Clopidogrel Bisulfate and Omeprazole. Postmarket Drug Safety Information for Patients and Providers. Postmarket Drug Safety Information for Patients and Providers: U.S. Food and Drug Administration. Last revised November 2009. Accessed December 25, 2012
   Google Scholar
• Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533-49
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101
   PubMed Web of Science ®Google Scholar
• Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301:2120-8
   PubMed Web of Science ®Google Scholar
• Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170(9):784-90
   PubMedGoogle Scholar
• Loyd RA, McClellan DA. Update on the evaluation and management of functional dyspepsia. Am Fam Physician 2011;83:547-52
   Google Scholar
• Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev (Online) 2006;CD001960
   Google Scholar
• Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007;22:304-10
   PubMed Web of Science ®Google Scholar
• Veldhuyzen van Zanten SJ, Jones MJ, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689-96
   PubMed Web of Science ®Google Scholar
• Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004;102:735-7. 60
   Google Scholar
• Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-6
   PubMed Web of Science ®Google Scholar
• Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert. opin Investig Drugs 2010;19:765-75
   PubMed Web of Science ®Google Scholar
• Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19:379-90
   PubMed Web of Science ®Google Scholar
• Van de Mierop L, Rutgeerts L, Van den Langenbergh B, Staessen A. Oral domperidone in chronic postprandial dyspepsia. A double-blind placebo-controlled evaluation. Digestion 1979;19:244-50
   PubMed Web of Science ®Google Scholar
• Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995;274:1780-2
   PubMed Web of Science ®Google Scholar
• Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997;12:952-7
   PubMed Web of Science ®Google Scholar
• Yoshii K, Hirayama M, Nakamura T, et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. J Pharm Sci 2011;100:4965-73
   PubMed Web of Science ®Google Scholar
• Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24:540-5. e250-1
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821-8
   PubMed Web of Science ®Google Scholar
• Arts J, Caenepeel P, Verbeke K, et al. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54:455-60
   PubMed Web of Science ®Google Scholar
• Moshiree B, McDonald R, Hou W, et al. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010;55:675-83
   PubMed Web of Science ®Google Scholar
• Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001;49:395-401
   PubMed Web of Science ®Google Scholar
• Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303:218-25
   PubMed Web of Science ®Google Scholar
• Talley NJ, Boyce P, Jones M. Dyspepsia and health care seeking in a community: how important are psychological factors? Dig Dis Sci 1998;43:1016-22
   PubMedGoogle Scholar
• Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30-6
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Otto M, Finnerup NB, et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409
   PubMed Web of Science ®Google Scholar
• Clouse RE, Lustman PJ, Geisman RA, et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-16
   PubMed Web of Science ®Google Scholar
• Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72
   PubMed Web of Science ®Google Scholar
• Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31
   PubMed Web of Science ®Google Scholar
• Tack J, Broekaert D, Coulie B, et al. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003;17:603-8
   PubMed Web of Science ®Google Scholar
• Chial HJ, Camilleri M, Burton D, et al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003;284:G130-7
   PubMed Web of Science ®Google Scholar
• van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008;6:746-52. quiz 18
   PubMed Web of Science ®Google Scholar
• Braak B, Klooker TK, Wouters MM, et al. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;34:638-48
   PubMed Web of Science ®Google Scholar
• Grover M, Drossman DA. Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol 2008;8:715-23
   Google Scholar
• Talley NJ, Locke GR III, Herrick LM, et al. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials 2012;33:523-33
   Google Scholar
• Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008;28:1326-33
   PubMed Web of Science ®Google Scholar
• Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-45
   PubMed Web of Science ®Google Scholar
• Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-87
   PubMed Web of Science ®Google Scholar
• Krueger D, Gruber L, Buhner S, et al. The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine. Neurogastroenterol Motil 2009;21:1203-e110
   PubMed Web of Science ®Google Scholar
• Melzer J, Rosch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004;20:1279-87
   PubMed Web of Science ®Google Scholar
• Rosch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002;40:401-8
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Conboy L, Kelley JM, et al. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol 2009;104:1489-97
   PubMed Web of Science ®Google Scholar
• Liu S, Peng S, Hou X, et al. Transcutaneous electroacupuncture improves dyspeptic symptoms and increases high frequency heart rate variability in patients with functional dyspepsia. Neurogastroenterol Motil 2008;20:1204-11
   PubMed Web of Science ®Google Scholar
• Xu S, Hou X, Zha H, et al. Electroacupuncture accelerates solid gastric emptying and improves dyspeptic symptoms in patients with functional dyspepsia. Dig Dis Sci 2006;51:2154-9
   PubMed Web of Science ®Google Scholar
• Calvert EL, Houghton LA, Cooper P, et al. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002;123:1778-85
   PubMed Web of Science ®Google Scholar
• Barber A, Bartoszyk GD, Bender HM, et al. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994;113:1317-27
   PubMed Web of Science ®Google Scholar
• Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237-46
   PubMed Web of Science ®Google Scholar
• Talley NJ, Choung RS, Camilleri M, et al. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008;27:1122-31
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Holvoet L, Vandenberghe J, et al. Do we have an alternative for the Rome III gastroduodenal symptom-based subgroups in functional gastroduodenal disorders? A cluster analysis approach. Neurogastroenterol Motil 2011;23:730-8
   PubMed Web of Science ®Google Scholar
• Kindt S, Van Oudenhove L, Mispelon L, et al. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol 2011;106:340-8
   PubMed Web of Science ®Google Scholar
• Hogan SP, Mishra A, Brandt EB, et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol 2001;2:353-60
   PubMed Web of Science ®Google Scholar
• Jacoby DB, Gleich GJ, Fryer AD. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 1993;91:1314-18
   PubMed Web of Science ®Google Scholar
• Powell N, Beech B, Huntley T, et al. Increased prevalence of gastrointestinal symptoms in patients with allergic disease. Postgrad Med J 2007;83:182-6
   PubMed Web of Science ®Google Scholar